TTR and cardiac amyloidosis: In fact, the Clinical Genome Resource Actionability Working Group has recently upgraded its assertion for TTR and cardiac amyloidosis to “strong actionability” (7); however, they do note that there is limited evidence informing disease likelihood and intervention effectiveness in this context.